Stuart Holden

Title(s)HS Clinical Professor, Urology
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. MRI-guided Dose-escalated Salvage Radiotherapy for Bulky Bladder Neck Recurrence of Prostate Cancer. Cureus. 2018 Mar 22; 10(3):e2360. Kishan AU, Tyran M, Steinberg ML, Holden SB, Cao M. PMID: 29805929; PMCID: PMC5963943.
      View in: PubMed   Mentions:
    2. Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right? J Clin Oncol. 2018 04 01; 36(10):937-941. Faiena I, Holden S, Cooperberg MR, Holden S, Soule HR, Simons JW, Morgan TM, Penson DF, Morgans AK, Hussain M. PMID: 29401003; PMCID: PMC6804825.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    3. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. Urol Oncol. 2017 05; 35(5):272-278. Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K. PMID: 28065395.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    4. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017 02; 35(2):39.e1-39.e7. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. PMID: 28341495.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    5. Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. Urology. 2017 Jan; 99:270-277. Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K. PMID: 27720772.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    6. Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2017 01; 197(1):14-22. Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K. PMID: 27460757.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    7. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015 Jan; 47(1):1-3. Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. PMID: 25474525.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med. 2014 Oct; 138(10):1387-405. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME. PMID: 25092589.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    9. The integrated proactive surveillance system for prostate cancer. Open Med Inform J. 2012; 6:1-8. Wang H, Yatawara M, Huang SC, Dudley K, Szekely C, Holden S, Piantadosi S. PMID: 22505956; PMCID: PMC3322433.
      View in: PubMed   Mentions: 1  
    10. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. PMID: 16536755.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCTClinical Trials
    11. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB. PMID: 15193259.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    12. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 2000 Oct 01; 60(19):5494-8. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. PMID: 11034093.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    13. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo . Prostate. 2000 Feb 15; 42(3):163-71. Kubota T, Hisatake J, Hisatake Y, Said JW, Chen SS, Holden S, Taguchi H, Koeffler HP. PMID: 10639186.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    14. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998 Aug 01; 58(15):3344-52. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. PMID: 9699665.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansAnimalsCells
    15. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 1997 Aug; 19(1):15-27. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. PMID: 9278857.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    16. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate. 1997 Jul 01; 32(2):115-21. de Vos S, Dawson MI, Holden S, Le T, Wang A, Cho SK, Chen DL, Koeffler HP. PMID: 9215399.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    17. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate. 1997 May 01; 31(2):77-83. de Vos S, Holden S, Heber D, Elstner E, Binderup L, Uskokovic M, Rude B, Chen DL, Le J, Cho SK, Koeffler HP. PMID: 9140119.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    Stuart's Networks
    Concepts (140)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB02.

    Copyright © The Regents of the University of California